A strain B84 producing surfactin and bacillomycin D lipopeptides was identified as Bacillus amyloliquefaciens. B84 lipopeptides were extracted by acid precipitation, identified by mass spectrometry and loaded onto chitosan nanoparticles by ionotropic gelation process. The lipopeptide / chitosan nanoparticles have an average size of 569 nm, a zeta potential range of 38.8 mV and encapsulation efficiency (EE) of 85.58 %. The treatment of C. albicans cells with encapsulated lipopeptides showed an anti-adhesive activity of 81.17 % and a decreased effect of cell surface hydrophobicity « CSH » by 25.53%. An anti-leishmanial activity was also recorded with IC50 of 14.37 µg ml-1 and 22.45 µg mL-1 against L. major promastigote and amastigote forms, respectively. Cytotoxicity studies on human cells showed low cytotoxicity effect with HC50 value of 770 µg mL-1 towards human red blood cells and LC50 value of 234.56 µg mL-1 towards macrophage Raw 264.7 cell line. These lipopeptide / chitosan nanoparticles could be used as a potential delivery system of lipopeptides to improve both their anti-adhesive effect against C. albicans cells colonizing medical devices and their anti-infectious activity against leishmania.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Loading...
Posted 19 Mar, 2021
Invitations sent on 02 Apr, 2021
Received 15 Mar, 2021
On 14 Mar, 2021
On 12 Mar, 2021
Posted 19 Mar, 2021
Invitations sent on 02 Apr, 2021
Received 15 Mar, 2021
On 14 Mar, 2021
On 12 Mar, 2021
A strain B84 producing surfactin and bacillomycin D lipopeptides was identified as Bacillus amyloliquefaciens. B84 lipopeptides were extracted by acid precipitation, identified by mass spectrometry and loaded onto chitosan nanoparticles by ionotropic gelation process. The lipopeptide / chitosan nanoparticles have an average size of 569 nm, a zeta potential range of 38.8 mV and encapsulation efficiency (EE) of 85.58 %. The treatment of C. albicans cells with encapsulated lipopeptides showed an anti-adhesive activity of 81.17 % and a decreased effect of cell surface hydrophobicity « CSH » by 25.53%. An anti-leishmanial activity was also recorded with IC50 of 14.37 µg ml-1 and 22.45 µg mL-1 against L. major promastigote and amastigote forms, respectively. Cytotoxicity studies on human cells showed low cytotoxicity effect with HC50 value of 770 µg mL-1 towards human red blood cells and LC50 value of 234.56 µg mL-1 towards macrophage Raw 264.7 cell line. These lipopeptide / chitosan nanoparticles could be used as a potential delivery system of lipopeptides to improve both their anti-adhesive effect against C. albicans cells colonizing medical devices and their anti-infectious activity against leishmania.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Loading...